Correlations between macrophage/microglial activation marker sTREM-2 and measures of T-cell activation, neuroaxonal damage and disease severity in multiple sclerosis

por Ioannides, Zara A, Csurhes, Peter A, Swayne, Andrew, Foubert, Philippe, Aftab, Blake T, Pender, Michael P
Publicado 2021

Sustained Clinical Improvement in a Subset of Patients With Progressive Multiple Sclerosis Treated With Epstein–Barr Virus-Specific T Cell Therapy

por Ioannides, Zara A., Csurhes, Peter A., Douglas, Nanette L., Mackenroth, Gem, Swayne, Andrew, Thompson, Kate M., Hopkins, Tracey J., Green, Kerryn A., Blum, Stefan, Hooper, Kaye D., Wyssusek, Kerstin H., Coulthard, Alan, Pender, Michael P.
Publicado 2021

Hypermetabolism in ALS is associated with greater functional decline and shorter survival

por Steyn, Frederik J, Ioannides, Zara A, van Eijk, Ruben P A, Heggie, Susan, Thorpe, Kathryn A, Ceslis, Amelia, Heshmat, Saman, Henders, Anjali K, Wray, Naomi R, van den Berg, Leonard H, Henderson, Robert D, McCombe, Pamela A, Ngo, Shyuan T
Publicado 2018

Epstein-Barr virus–specific T cell therapy for progressive multiple sclerosis

por Pender, Michael P., Csurhes, Peter A., Smith, Corey, Douglas, Nanette L., Neller, Michelle A., Matthews, Katherine K., Beagley, Leone, Rehan, Sweera, Crooks, Pauline, Hopkins, Tracey J., Blum, Stefan, Green, Kerryn A., Ioannides, Zara A., Swayne, Andrew, Aftab, Blake T., Hooper, Kaye D., Burrows, Scott R., Thompson, Kate M., Coulthard, Alan, Khanna, Rajiv
Publicado 2020